Exploratory Open Label Dose-escalation Phase Ib Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO5323441, Administered Intravenously, in Combination With Sorafenib (Nexavar), in Patients With Advanced or Metastatic and/or Unresectable Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2017
At a glance
- Drugs THR 317 (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 21 May 2012 Actual patient number 6 added as reported by ClinicalTrials.gov.
- 21 May 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov.